Role of SCA2 mutations in early- and late-onset dopa-responsive parkinsonism.
Kock
Norman
N
Müller
Birgitt
B
Vieregge
Peter
P
Pramstaller
Peter P
PP
Marder
Karen
K
Abbruzzese
Giovanni
G
Martinelli
Paolo
P
Lang
Anthony E
AE
Jacobs
Helfried
H
Hagenah
Johann
J
Harris
Juliette
J
Meija-Santana
Helen
H
Fahn
Stanley
S
Hedrich
Katja
K
Kann
Martin
M
Gehlken
Ulrike
U
Culjkovic
Biljana
B
Schwinger
Eberhard
E
Wszolek
Zbigniew K
ZK
Zühlke
Christine
C
Klein
Christine
C
D017668:Age of Onset; D000067528:Ataxins; D004295:Dihydroxyphenylalanine / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000627:therapeutic use*; D004351:Drug Resistance; D006801:Humans; D009419:Nerve Tissue Proteins; D020734:Parkinsonian Disorders / Q000188:drug therapy* / Q000453:epidemiology / Q000235:genetics*; D011506:Proteins / Q000235:genetics*
D000067528:Ataxins; D015259:Dopamine Agents; D009419:Nerve Tissue Proteins; D011506:Proteins; D004295:Dihydroxyphenylalanine